HomeInsightsStock Comparison

Biocon Ltd vs Cohance Lifesciences Ltd Stock Comparison

Biocon Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: Jun 20, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 348.25 as of 20 Jun 11:25.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 31 on March 2024 . This represents a CAGR of -6.51% over 5 yearsThe P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 31707 crore on March 2024 . This represents a CAGR of -0.48% over 5 yearsThe Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Biocon Ltd for the Mar '25 is ₹ 4474 crore as compare to the Dec '24 revenue of ₹ 3874 crore. This represent the growth of 15.49% The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79%.
  • The ebitda of Biocon Ltd for the Mar '25 is ₹ 1135 crore as compare to the Dec '24 ebitda of ₹ 804.7 crore. This represent the growth of 41.11% The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 459.4 crore over 8 quarters. This represents a CAGR of 75.65% The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 50.32 % on March 2024 . This represents a CAGR of -10.30% over 3 yearsThe Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Biocon Ltd News Hub

News

Biocon get facilities rated

CRISIL Ratings Limited has re-affirmed the Long Term rating of Biocon at CRISIL AA+/Stable...

Read more

18 Jun 2025 09:41

News

Biocon Ltd soars 3.52%, Gains for third straight session

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, ...

Read more

11 Jun 2025 13:05

News

Biocon gets CDSCO approval for Liraglutide drug substance

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for ...

Read more

03 Jun 2025 08:23

News

Biocon Ltd spurts 1.3%, up for five straight sessions

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1...

Read more

19 May 2025 13:00

News

Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and...

Read more

16 May 2025 09:38

News

Board of Biocon recommends final dividend

Biocon announced that the Board of Directors of the Company at its meeting held on 8 May 2...

Read more

09 May 2025 09:23

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Suven Pharmaceuticals Ltd

Which company has a larger market capitalization, Biocon Ltd or Suven Pharmaceuticals Ltd?

Market cap of Biocon Ltd is 41,852 Cr while Market cap of Suven Pharmaceuticals Ltd is 37,853 Cr

What are the key factors driving the stock performance of Biocon Ltd and Suven Pharmaceuticals Ltd?

The stock performance of Biocon Ltd and Suven Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Suven Pharmaceuticals Ltd?

As of June 20, 2025, the Biocon Ltd stock price is INR ₹348.6. On the other hand, Suven Pharmaceuticals Ltd stock price is INR ₹989.45.

How do dividend payouts of Biocon Ltd and Suven Pharmaceuticals Ltd compare?

To compare the dividend payouts of Biocon Ltd and Suven Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions